Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 27, 2007
JNCI Journal of the National Cancer Institute 2007 99(13):986-987; doi:10.1093/jnci/djm029
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/13/986    most recent
djm029v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Woo, S.-B.
Right arrow Articles by Solomon, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woo, S.-B.
Right arrow Articles by Solomon, D. H.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Bisphosphonate Therapy for Cancer and Prevalence of Inflammatory Jaw Conditions

Sook-Bin Woo, Daniel H. Solomon

Affiliations of authors: Divisions of Oral and Maxillofacial Surgery, Oral Medicine and Dentistry (SBW), Rheumatology (DHS), and Pharmacoepidemiology (DHS), Brigham and Women's Hospital, Boston, MA

Correspondence to: Sook-Bin Woo, DMD, MMSc, Division of Oral and Maxillofacial Surgery, Oral Medicine and Dentistry, Brigham and Women's Hospital Surgery, 1620 Tremont St, Ste 3-028, Boston, MA 02120 (e-mail: swoo@partners.org).

The first 10% of the full text of this article appears below.

Patients with multiple myeloma and metastatic cancer to the bones show reduced incidence of skeletal-related events when they are treated with intravenous bisphosphonates such as pamidronate or zoledronic acid (1,2). For many years, the continuous, often monthly, use of bisphosphonates in such patients was not questioned. However, in 2003, an adverse reaction, termed bisphosphonate-associated osteonecrosis of the jaws, was reported in this patient population (3,4). To date, more than 600 cases have been reported, but it is likely that many more exist. The prevalence of osteonecrosis of the jaws in the oncologic population was 6%–11% in small single-center retrospective studies (5–. . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis
Gregg S. Wilkinson, Yong-Fang Kuo, Jean L. Freeman, and James S. Goodwin
J Natl Cancer Inst 2007 99: 1016-1024. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 981. [Extract] [Full Text] [PDF]

Press Release: Bisphosphonate Treatment Is Associated with Jaw Bone Problems
Liz Savage
J Natl Cancer Inst 2007 99: 981. [Extract] [Full Text]